Anti-platelet therapy: phosphodiesterase inhibitors.

Br J Clin Pharmacol 2011 Oct;72(4):634-46

Department of Internal Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy.

Inhibition of platelet aggregation can be achieved either by the blockade of membrane receptors or by interaction with intracellular signalling pathways. Cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP) are two critical intracellular second messengers provided with strong inhibitory activity on fundamental platelet functions. Phosphodiesterases (PDEs), by catalysing the hydrolysis of cAMP and cGMP, limit the intracellular levels of cyclic nucleotides, thus regulating platelet function. The inhibition of PDEs may therefore exert a strong platelet inhibitory effect. Platelets possess three PDE isoforms (PDE2, PDE3 and PDE5), with different selectivity for cAMP and cGMP. Several nonselective or isoenzyme-selective PDE inhibitors have been developed, and some of them have entered clinical use as antiplatelet agents. This review focuses on the effect of PDE2, PDE3 and PDE5 inhibitors on platelet function and on the evidence for an antithrombotic action of some of them, and in particular of dipyridamole and cilostazol.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2011.04034.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195739PMC
October 2011
8 Reads

Publication Analysis

Top Keywords

pde2 pde3
8
pde3 pde5
8
platelet function
8
camp cgmp
8
platelet
5
inhibition pdes
4
pdes exert
4
function inhibition
4
regulating platelet
4
therapy phosphodiesterase
4
exert strong
4
strong platelet
4
possess three
4
platelets possess
4
inhibitory platelets
4
platelet inhibitory
4
nucleotides regulating
4
levels cyclic
4
functions phosphodiesterases
4
phosphodiesterases pdes
4

References

(Supplied by CrossRef)

Daniel et al.
2002
Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP
Maurice et al.
Mol Pharmacol 1990
Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles
Sutherland et al.
J Biol Chem 1958
Adenosine 3′-5′-phosphate in biological materials. Purification and properties of cyclic 3′-5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′-5′-phosphate in human urine
Butcher et al.
J Biol Chem 1962
A1- and A2-selective adenosine antagonists: in vivo characterization of cardiovascular effects
Evoniuk et al.
J Pharmacol Exp Ther 1987

Similar Publications